Systemic dendrimer-drug treatment of ischemia-induced neonatal white matter injury
- PMID: 26184052
- PMCID: PMC4732874
- DOI: 10.1016/j.jconrel.2015.07.009
Systemic dendrimer-drug treatment of ischemia-induced neonatal white matter injury
Abstract
Extreme prematurity is a major risk factor for perinatal and neonatal brain injury, and can lead to white matter injury that is a precursor for a number of neurological diseases, including cerebral palsy (CP) and autism. Neuroinflammation, mediated by activated microglia and astrocytes, is implicated in the pathogenesis of neonatal brain injury. Therefore, targeted drug delivery to attenuate neuroinflammation may greatly improve therapeutic outcomes in models of perinatal white matter injury. In this work, we use a mouse model of ischemia-induced neonatal white matter injury to study the biodistribution of generation 4, hydroxyl-functionalized polyamidoamine dendrimers. Following systemic administration of the Cy5-labeled dendrimer (D-Cy5), we demonstrate dendrimer uptake in cells involved in ischemic injury, and in ongoing inflammation, leading to secondary injury. The sub-acute response to injury is driven by astrocytes. Within five days of injury, microglial proliferation and migration occurs, along with limited differentiation of oligodendrocytes and oligodendrocyte death. From one day to five days after injury, a shift in dendrimer co-localization occurred. Initially, dendrimer predominantly co-localized with astrocytes, with a subsequent shift towards microglia. Co-localization with oligodendrocytes reduced over the same time period, demonstrating a region-specific uptake based on the progression of the injury. We further show that systemic administration of a single dose of dendrimer-N-acetyl cysteine conjugate (D-NAC) at either sub-acute or delayed time points after injury results in sustained attenuation of the 'detrimental' pro-inflammatory response up to 9days after injury, while not impacting the 'favorable' anti-inflammatory response. The D-NAC therapy also led to improvement in myelination, suggesting reduced white matter injury. Demonstration of treatment efficacy at later time points in the postnatal period provides a greater understanding of how microglial activation and chronic inflammation can be targeted to treat neonatal brain injury. Importantly, it may also provide a longer therapeutic window.
Keywords: Dendrimer; Ischemia; Microglia; Neonatal; Neuroinflammation; Targeted delivery.
Copyright © 2015 Elsevier B.V. All rights reserved.
Figures
Similar articles
-
Uptake of dendrimer-drug by different cell types in the hippocampus after hypoxic-ischemic insult in neonatal mice: Effects of injury, microglial activation and hypothermia.Nanomedicine. 2017 Oct;13(7):2359-2369. doi: 10.1016/j.nano.2017.06.014. Epub 2017 Jun 30. Nanomedicine. 2017. PMID: 28669854 Free PMC article.
-
Systemic dendrimer-drug nanomedicines for long-term treatment of mild-moderate cerebral palsy in a rabbit model.J Neuroinflammation. 2020 Oct 25;17(1):319. doi: 10.1186/s12974-020-01984-1. J Neuroinflammation. 2020. PMID: 33100217 Free PMC article.
-
Microglial migration and interactions with dendrimer nanoparticles are altered in the presence of neuroinflammation.J Neuroinflammation. 2016 Mar 22;13(1):65. doi: 10.1186/s12974-016-0529-3. J Neuroinflammation. 2016. PMID: 27004516 Free PMC article.
-
White matter injury in the neonatal hypoxic-ischemic brain and potential therapies targeting microglia.J Neurosci Res. 2021 Apr;99(4):991-1008. doi: 10.1002/jnr.24761. Epub 2021 Jan 8. J Neurosci Res. 2021. PMID: 33416205 Review.
-
Consequences of oxygen deprivation on myelination and sex-dependent alterations.Mol Cell Neurosci. 2023 Sep;126:103864. doi: 10.1016/j.mcn.2023.103864. Epub 2023 Jun 1. Mol Cell Neurosci. 2023. PMID: 37268283 Review.
Cited by
-
Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands.J Nanobiotechnology. 2024 May 17;22(1):260. doi: 10.1186/s12951-024-02511-7. J Nanobiotechnology. 2024. PMID: 38760847 Free PMC article. Review.
-
Mitochondria-Targeted Antioxidant Therapeutics for Traumatic Brain Injury.Antioxidants (Basel). 2024 Feb 29;13(3):303. doi: 10.3390/antiox13030303. Antioxidants (Basel). 2024. PMID: 38539837 Free PMC article. Review.
-
Nanomaterial payload delivery to central nervous system glia for neural protection and repair.Front Cell Neurosci. 2023 Oct 24;17:1266019. doi: 10.3389/fncel.2023.1266019. eCollection 2023. Front Cell Neurosci. 2023. PMID: 37941607 Free PMC article. Review.
-
Key roles of glial cells in the encephalopathy of prematurity.Glia. 2024 Mar;72(3):475-503. doi: 10.1002/glia.24474. Epub 2023 Nov 1. Glia. 2024. PMID: 37909340 Free PMC article. Review.
-
The role and potential therapeutic targets of astrocytes in central nervous system demyelinating diseases.Front Cell Neurosci. 2023 Sep 1;17:1233762. doi: 10.3389/fncel.2023.1233762. eCollection 2023. Front Cell Neurosci. 2023. PMID: 37720543 Free PMC article. Review.
References
-
- Johnson S. Cognitive and behavioural outcomes following very preterm birth. Seminars in fetal & neonatal medicine. 2007;12:363–373. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous